HDAC9 and lung carcinoma: A recent report showed that the co-treatment of lung cancer cells with IFN-γ and MEK and/or histone deacetylase (HDAC) inhibitors induced MHC-II expression in IFN-γ-resistant cells.47 In agreement with that, we observed expression of MHC-II in our PDAC cell lines when treated with IFN-γ in the presence of the MEK inhibitor trametinib and the HDAC inhibitor TSA.